Oppenheimer Says Raptor Pharma (RPTP) Procysbi Delay Immaterial, Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
FDA Extends Review of Raptor Pharma (RPTP) PROCYSBI NDA
December 24, 2012 8:43 AM ESTRaptor Pharmaceutical Corp. (Nasdaq: RPTP), this weekend announced that the U.S. Food and Drug Administration will require additional time to complete its review of the New Drug Application ("NDA") for RP103 (PROCYSBI), for the potential treatment of nephropathic cystinosis. In a notice... More
